RxDoctor Payments Data

Mithaq Vahedi, MD

Ophthalmology · Eau Claire, WINPI 1942565890

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,725 of the $5,803 with a category attached, or 64.2%. 10 manufacturers reported payments, led by AbbVie at 39.7% of the total. Reporting peaked in 2022 at $2,097 and has fallen 96.7% since, to $68 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,803in general payments, 2019–2025

Across 65 payments — averaging $89.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$2K
  • Sight Sciences, Inc.$649
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$289
  • Regeneron$125
  • Aerie Pharmaceuticals, Inc.$119
  • plus $288 from 4 others

What the payments were for

  • Travel & lodging$2,07836%
  • Food & beverage$3,72564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803 in reported general payments places this provider in the 90th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$33,164
Medicare patients
54
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate250$12,194
MoxifloxacinMoxifloxacin Hcl226$4,859
VyzultaLatanoprostene Bunod15$3,732
Latanoprost87$1,009
Brimonidine Tartrate23$820
Timolol Maleate34$493
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$358
Ketorolac Tromethamine16$355
Dorzolamide Hcl13$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$38$3,73215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →